Skip to main content

Cancer therapy: KRAS targeted therapies

Guest Editors

Biswarup Saha, MS, MTech, PhD, H. Lee Moffitt Cancer Center & Research Institute, USA
Hitendra Singh Solanki, PhD, H. Lee Moffitt Cancer Center & Research Institute, USA


BMC Cancer has published this Collection on Cancer therapy: KRAS targeted therapies. We invited contributions on various aspects, including new and emerging research, analyses of clinical treatments, and studies across cancer types.

Meet the Guest Editors

Back to top

Biswarup Saha, MS, MTech, PhD, H. Lee Moffitt Cancer Center & Research Institute, USA

As a scientist at the H. Lee Moffitt Cancer Center & Research Institute, Dr Saha’s fundamental research is based upon hippo signaling and its downstream mediator, focusing mainly on protooncogenic YAP1, and its associated molecular crosstalk under NFkB modulatory pathway in pan cancer. His research interests are: tumor biology, cancer stem cell, epigenetics, cell signaling, drug resistance, tumor microenvironment, extracellular matrix, and desmoplasia.

Hitendra Singh Solanki, PhD, H. Lee Moffitt Cancer Center & Research Institute, USA

Dr Solanki is a PhD scientist trained in cancer signaling, drug resistance in cancer and mass spectrometry-based phosphoproteomics. He uses multi-omics approaches to discern diverse mechanisms of adaptive and acquired resistance to KRAS (OFF)- and (ON)- state inhibitors in lung cancer.  His work primarily focused on conducting translational research and develop biomarkers to predict therapeutic responses in lung cancer.

About the Collection

One of the most frequently mutated oncogenes in human cancer, KRAS has long been considered “undruggable” with targeted therapy. As central drivers of cancer progressions, KRAS mutations function as oncogenic initiators, instigating the proliferation of malignant cells. The result is the rapid expansion of resistant malignant tissue. 

Targeting these mutations is imperative to advancing cancer therapy, and in light of recent developments in the field, BMC Cancer has published this Collection on Cancer therapy: KRAS targeted therapies. 

We encouraged submissions on a range of topics, including but not limited to:

  • Novel strategies, such as small molecule inhibitors, immunotherapies, and gene-based therapies, designed specifically for addressing KRAS-mutated cancers
  • Studies that assess the safety, effectiveness, and tolerability of KRAS targeted therapies across cancer types
  • Precise biomarkers and diagnostic tools
  • Potential synergistic effects arising from combining KRAS targeted agents with conventional cancer treatments
  • Mechanisms responsible for resistance to KRAS targeted therapies
  • Analyses of real-world clinical results


Image credit: LASZLO / Stock.adobe.com

  1. Major salivary gland tumors (MSGTs) are rare and pose significant treatment challenges. This study investigates the efficacy and safety of particle beam radiotherapy (PBRT) for patients with newly-diagnosed MS...

    Authors: Qingting Huang, Jiyi Hu, Weixu Hu, Jing Gao, Haojiong Zhang, Jiade Jay Lu and Lin Kong
    Citation: BMC Cancer 2025 25:452
    Content type: Research Published on:

  2. KRAS (Kirsten rat sarcoma viral oncogene homolog) gene mutation is one of the common driver gene mutations in non-small cell lung cancer (NSCLC) with poor prognosis. There are limited effective treatments for ...

    Authors: Kunchen Wei, Tiansheng Sun, Xiao Feng, Yang Chen, Qingzhong Liu and Hao Tang
    Citation: BMC Cancer 2025 25:444
    Content type: Research Published on:

  3. Metastatic colorectal cancer (mCRC) poses a high rate of morbidity and mortality despite various treatment advances. Cetuximab, an anti-EGFR, has shown promising efficacy in improving outcomes when combined wi...

    Authors: Marryam Azeem, Anees ur Rehman, Saba Rasheed, Aleena Shahzad, Muhammad Hamza Javed, Qurratul Ain Jamil, Hidayah Karuniawati and Saleh Karamah Al-Tamimi
    Citation: BMC Cancer 2025 25:331
    Content type: Research Published on:

  4. Small-molecule compounds that even partially restore the GTPase activity of RASG12V can be used in anticancer therapy. Until now, attempts to obtain such compounds have failed. Compounds with this ability have be...

    Authors: Aneta Wlodarczyk, Cezary Treda, Marcin Pacholczyk, Adrianna Rutkowska, Marta Wegierska, Amelia Kierasinska-Kalka, Katarzyna Wasiak, Damian Ciunowicz, Dagmara Grot, Pawel Glowacki, Ewelina Stoczynska-Fidelus and Piotr Rieske
    Citation: BMC Cancer 2025 25:182
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select Cancer therapy: KRAS targeted therapies from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.